IP Library Granted Patent US 9,242,980
Granted Patent B2
US 9,242,980 · App. 13/817,214 · Granted Jan 26, 2016

Lipidated immune response modifier compound compositions, formulations, and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,242,980
App. No.
13/817,214
Granted
Jan 26, 2016
Kind
B2
Abstract

The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.

Claims (16)

1. A compound of formula:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of claim 1 .

3. A pharmaceutical composition comprising the compound of claim 1 in a formulation comprising liposomes.

4. The pharmaceutical composition of claim 2 , further comprising an antigen.

5. The pharmaceutical composition of claim 4 , wherein the compound and antigen are admixed into a single composition.

6. The pharmaceutical composition of claim 4 , wherein the compound and antigen are present in separate components of the composition to be administered in combination.

7. The pharmaceutical composition of claim 4 wherein the antigen is a cancer vaccine.

8. The pharmaceutical composition of claim 4 wherein the antigen is a viral vaccine.

9. A method of enhancing the effectiveness of a vaccine antigen by administering as a vaccine adjuvant the compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide, or a pharmaceutically acceptable salt thereof.

10. The method of claim 9 , wherein the compound is incorporated into a liposome formulation.

11. The pharmaceutical composition of claim 3 , further comprising an antigen.

12. The pharmaceutical composition of claim 4 , wherein the antigen is an influenza vaccine.

13. The pharmaceutical composition of claim 4 , wherein the antigen is at least one hemagglutinin antigen.

14. The method of claim 9 , wherein the vaccine antigen is at least one influenza antigen.

15. The method of claim 9 , wherein the vaccine antigen is at least one hemagglutinin antigen.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: 3M INNOVATIVE PROPERTIES COMPANY
To: SOLVENTUM INTELLECTUAL PROPERTIES COMPANY
Reel/Frame 066430/0193 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2013
From: WIGHTMAN, PAUL D.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 030457/0405 →